CED Life Science Conference 2018 - presenting at the Coulter Investment Forum
Year Founded: 2013
Kerberos has elucidated the crucial role of the chemokine receptor CX3CR1 and its ligand Fractalkine in regulating the seeding and growth of breast cancer cells to skeleton and soft-tissue organs. Kerberos has synthesized novel, potent and selective small-molecule antagonists to target CX3CR1 receptor and have provided pre-clinical validation of their activity in animal models with high translational relevance.
Clinical proof of principle will be obtained in phase-Ib and phase-II clinical studies on Inflammatory Breast Cancer (IBC) patients, as this tumor progresses dramatically faster than adenocarcinoma. IBC is often difficult to diagnose because it does not usually present with a lump. 35% of women are diagnosed with IBC at an advanced stage and with metastatic disease, in contrast to less than 5% of patients with breast adenocarcinoma. As such, the few treatment options available for IBC are not curative and survival rates at five years are very low.
We have developed a series of small molecule CX3CR1 antagonists to be used in combination with the current standard of care, which for IBC include chemotherapy and / or targeted therapy. Kerberos has a potential IND development candidate (FX-68) which is currently being profiled.
Richard Labaudiniere, PhD, Chairman: Former CEO of FoldRx Pharmaceuticals.
Kevin Taylor, CEO: Seasoned Pharma and Biotech corporate development executive officer.
Alessandro Fatatis, MD, PhD, CSO: Professor of Pharmacology and Pathology at Drexel University College of Medicine.
Shawn Bridy, MA, MBA, CFO: Venture Partner for Militia Hill Ventures, Former Head of Business Development for Immunome.
Olimpia Meucci, MD, PhD, Head, Preclinical Development: Professor and Chair, Department of Pharmacology and Physiology & Director, Center of Neuroimmunology and CNS Therapeutics, Institute of Molecular Medicine and Infectious Diseases, at Drexel University College of Medicine.
Joseph Salvino, PhD, Head, Drug Discovery: Professor of Medicinal Chemistry and Scientific Director at The Wistar Institute and Cancer Center.
KEY MILESTONES TO DATE
- Founders have been awarded over $4.5M in grant and research funding to date
- Coulter award – Q3 2017
- SBIR Phase II awarded - September 2017
Kevin Taylor, (610) 570-9279
3001 Market Street, Suite 140, Philadelphia, PA 19104
Learn more about the CED Life Science Conference.